Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

IMPACT OF FRUCTOSE ON METABOLISM, ENERGY HOMEOSTASIS AND MR BIOMARKERS IN NAFLD

F Manal
Duke Universitycity: Durham    country: United States (us)

Grant 1R01DK093568-01 from National Institute Of Diabetes And Digestive And Kidney Diseases

Abstract: To define the mechanism(s) by which fructose may contribute to nonalcoholic fatty liver disease (NAFLD) progression and assess whether such factors can be measured using magnetic resonance (MR) biomarkers and modified with dietary fructose restriction. Background NAFLD is a major public health concern which is anticipated to surpass the morbidity and mortality of other forms of chronic liver disease by 2020. Both the prevalence and severity of NAFLD have been associated with increased consumption of fructose. We have reported that increased fructose consumption is associated with decreased hepatic steatosis, liver injury (necroinflammation and hepatocyte ballooning) and fibrosis in a dose-dependent manner. The unique metabolism of fructose, one which depletes hepatic ATP, increases uric acid, and worsens features of insulin resistance, is a potential mechanism that may account for fructose-related liver injury in NAFLD. Given the changes which occur with fructose exposure, fructose is an ideal diagnostic "tool" by which to induce and/or amplify changes in quantitative MR-based biomarkers and "target" for dietary intervention studies for the treatment of NAFLD. Hypothesis We hypothesize that fructose is a risk factor for hepatic steatosis, steatohepatitis, and advanced fibrosis and that acute and chronic fructose exposure will worsen the metabolic, energy homeostatic and associated MR-based biomarkers features of NAFLD. Further, we hypothesize that dietary fructose restriction will improve these metabolic and energy homeostatic derangements. Approach Quantitative MR biomarkers of hepatic metabolites and energy homeostasis will be evaluated before, during, and after acute/chronic fructose challenges. We will characterize the pathophysiologic changes which occur with fructose exposure using multi-parametric analysis of MRI and 1H and 31P and spectroscopic imaging data to measures of metabolism and energy homeostasis and relate these to the histologic features of NAFLD. Impact This work addresses the following significant gaps in knowledge 1) whether acute and chronic fructose exposure alters metabolism, energy homeostasis, and is associated with liver injury in patients with/without NAFLD and 2) whether modification of fructose consumption could improve the clinical and pathologic features of NAFLD. The successful completion of the proposed studies will provide novel and clinically relevant information regarding the pathophysiologic and pathologic mechanism underlying fructose-related liver injury in humans. The proposed studies will be the first to correlate the dynamic measures of non-invasive MR-based biomarkers and energy homeostasis with the clinical, metabolic and histologic features of NAFLD. The integration of these biomarkers in a cross-sectional and longitudinal study will characterize their use for measuring changes associated with fructose-related liver injury and facilitate the development of non-invasive biomarkers for NAFLD diagnosis and progression. The goal of this project is to define the mechanism(s) by which fructose may contribute to nonalcoholic fatty liver disease (NAFLD) progression, assess whether such factors can be measured using dynamic MRI/MRS biomarkers and whether these factors can be modified with dietary fructose restriction

Keywords: Accounting; Acute; Address; base; biomarker; Biopsy; Biotechnology; Chronic; Clinical; clinically relevant; cohort; Cohort Studies; Consumption; Data; Deposition; Development; Diagnostic; Dietary Intervention; Disease; disease diagnosis; Disease Progression; Distant; Dose; energy balance; Energy Metabolism; Fatty Liver; Fibrosis; Fructokinases; Fructose; Genetic Transcription; Goals; Hepatic; Hepatocyte; Histologic; Histology; Homeostasis; Hour; Human; Image; improved; Injury; Insulin Resistance; Intervention Studies; Knowledge; Lipids; Liver; Liver diseases; liver imaging; liver metabolism; Longitudinal Studies; Magnetic Resonance; Magnetic Resonance Imaging; Measurement; Measures; Metabolic; Metabolism; Methodology; Modification; Morbidity - disease rate; Mortality Vital Statistics; multidisciplinary; non-alcoholic fatty liver; nonalcoholic steatohepatitis; novel; Obesity; Pathologic; Patients; Prevalence; Process; Protocols documentation; public health medicine (field); Randomized; Recovery; Reporting; Risk Factors; Serum; Severities; spectroscopic imaging; Steatohepatitis; Surrogate Markers; Techniques; Tissue Banking; Tissue Banks; tool; United States National Institutes of Health; Uric Acid; Variant; volunteer; Water; Work

Relevance: The goal of this project is to define the mechanism(s) by which fructose may contribute to nonalcoholic fatty liver disease (NAFLD) progression, assess whether such factors can be measured using dynamic MRI/MRS biomarkers and whether these factors can be modified with dietary fructose restriction

Project start date: 2012-01-01

Project end date: 2014-12-31

Budget start date: 1-JAN-2012

Budget end date: 31-DEC-2012

1R01DK093568-01 (2012): $279328


Sponsored Links Excellgen http://Excellgen.com

Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950
Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950
Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500